Relevant provisions on donation of medical devices

pharmaceutical enterprises and medical and health institutions can sign agreements according to regulations. At the present stage when donation is not widespread and inexperienced, when pharmaceutical enterprises and medical and health institutions donate and receive gifts in a non-isolated way, all the agreements in the agreement should fully reflect the purpose of voluntary gratuity and public welfare. Pharmaceutical enterprises and medical and health institutions should pay attention to this, so as not to be suspected of commercial bribery and/or unfair competition because of the defects in the terms of the agreement.

1. Four points for attention when donating medical materials:

1. The recipient should be legal and compliant;

2. The donated medical materials should meet the quality standards;

3. Observe the donation procedure;

II. Donation process:

1. Internal decision-making of the donation unit;

2. Pre-evaluation by the recipient;

3. Sign the donation agreement;

4. Accept donations;

5. Information disclosure, supervision and management.

legal basis: article 17 of the drug administration law of the people's Republic of China * * * the state implements a unified drug safety information publication system. The general situation of national drug safety, warning information on drug safety risks, information on major drug safety incidents and their investigation and handling, and other information determined by the State Council that needs to be uniformly published shall be uniformly published by the drug supervision and administration department of the State Council. If the impact of drug safety risk warning information, major drug safety incidents and their investigation and handling information is limited to a specific area, it may also be published by the drug supervision and administration department of the people's government of the relevant province, autonomous region or municipality directly under the Central Government. The above information shall not be released without authorization.

drug safety information should be published in a timely, accurate and comprehensive manner, and necessary explanations should be made to avoid misleading.

no unit or individual may fabricate or disseminate false drug safety information.